Lance Alstodt has been appointed the Company’s President, Chief Executive Officer and Chairman of the Board as of Nov 16, 2020. Mr. Alstodt brings over 25 years of experience in leading medical technology and lifesciences companies in operations, capital raising activities, strategy, and mergers and acquisitions.
Most recently, Mr. Alstodt was the Founder and CEO of MedVest Consulting Corporation (“MedVest”), an advisory and capital firm focused exclusively within the healthcare sector, focusing on growth and channel strategy, strategic planning, merger and acquisition support and investor activities.
Prior to MedVest, Mr. Alstodt was a career investment banker with over 25 years of experience in healthcare investment banking, including mergers and acquisitions. In 2011, Mr. Alstodt joined Leerink Partners as Managing Director to help lead its medical technology sector. Mr. Alstodt brings significant domain experience within the orthopedic and spine specific sectors. From 2008-2011, Mr. Alstodt was a Managing Director and Head of Medical Technology at Oppenheimer & Co. From 2000-2008, he was a Managing Director in the Healthcare Group and Global M&A Group at Bank of America Merrill Lynch (“BAML”). Prior to BAML, Mr. Alstodt spent seven years in the Global M&A Group at J.P. Morgan Chase, where he worked extensively on acquisitions, leveraged buyouts, private and public financings, exclusive sales and general advisory assignments.
Mr. Alstodt received a B.A. in Economics from the State University of New York at Albany, with a secondary concentration in Finance and Marketing.
What is Lance Alstodt's net worth?
The estimated net worth of Lance Alstodt is at least $562,030.21 as of January 20th, 2023. Mr. Alstodt owns 186,721 shares of BioRestorative Therapies stock worth more than $562,030 as of January 28th. This net worth evaluation does not reflect any other investments that Mr. Alstodt may own. Learn More about Lance Alstodt's net worth.
How do I contact Lance Alstodt?
Has Lance Alstodt been buying or selling shares of BioRestorative Therapies?
During the last ninety days, Lance Alstodt has bought $2,178.00 of BioRestorative Therapies stock. Most recently, on Friday, January 20th, Lance Alstodt bought 200 shares of BioRestorative Therapies stock. The stock was acquired at an average cost of $3.13 per share, with a total value of $626.00. Following the completion of the transaction, the chief executive officer now directly owns 186,721 shares of the company's stock, valued at $584,436.73. Learn More on Lance Alstodt's trading history.
Who are BioRestorative Therapies' active insiders?
Are insiders buying or selling shares of BioRestorative Therapies?
During the last year, BioRestorative Therapies insiders bought shares 43 times. They purchased a total of 201,494 shares worth more than $984,160.62. The most recent insider tranaction occured on January, 20th when CEO Lance Alstodt bought 200 shares worth more than $626.00. Insiders at BioRestorative Therapies own 17.6% of the company.
Learn More about insider trades at BioRestorative Therapies. Information on this page was last updated on 1/20/2023.
